Kazia Releases Preliminary Cantrixil Phase I Data

Kazia Releases Preliminary Cantrixil Phase I Data

SYDNEY, June 19, 2018 /PRNewswire/ — Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to provide an interim update to shareholders regarding its phase I clinical trial of Cantrixil (TRX-E-002-1) in relapsed or recurrent ovarian cancer. The phase